|Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement|
D Moher, A Liberati, J Tetzlaff, DG Altman, PRISMA Group*
Annals of internal medicine 151 (4), 264-269, 2009
|Cochrane handbook for systematic reviews of interventions|
JPT Higgins, J Thomas, J Chandler, M Cumpston, T Li, MJ Page, ...
John Wiley & Sons, 2019
|The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration|
A Liberati, DG Altman, J Tetzlaff, C Mulrow, PC G°tzsche, JPA Ioannidis, ...
Journal of clinical epidemiology 62 (10), e1-e34, 2009
|The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials|
JPT Higgins, DG Altman, PC G°tzsche, P JŘni, D Moher, AD Oxman, ...
Bmj 343, 2011
|Meta-analysis of observational studies in epidemiology: a proposal for reporting|
DF Stroup, JA Berlin, SC Morton, I Olkin, GD Williamson, D Rennie, ...
Jama 283 (15), 2008-2012, 2000
|The PRISMA 2020 statement: an updated guideline for reporting systematic reviews|
MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, ...
Systematic reviews 10 (1), 1-11, 2021
|Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement|
D Moher, L Shamseer, M Clarke, D Ghersi, A Liberati, M Petticrew, ...
Systematic reviews 4 (1), 1-9, 2015
|PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation|
AC Tricco, E Lillie, W Zarin, KK O'Brien, H Colquhoun, D Levac, D Moher, ...
Annals of internal medicine 169 (7), 467-473, 2018
|The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials|
D Moher, KF Schulz, DG Altman, CONSORT Group*
Annals of internal medicine 134 (8), 657-662, 2001
|Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation|
L Shamseer, D Moher, M Clarke, D Ghersi, A Liberati, M Petticrew, ...
Bmj 349, 2015
|Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide|
TC Hoffmann, PP Glasziou, I Boutron, R Milne, R Perera, D Moher, ...
Bmj 348, 2014
|Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement|
D Moher, DJ Cook, S Eastwood, I Olkin, D Rennie, DF Stroup, ...
The Lancet 354 (9193), 1896-1900, 1999
|Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews|
BJ Shea, JM Grimshaw, GA Wells, M Boers, N Andersson, C Hamel, ...
BMC medical research methodology 7 (1), 1-7, 2007
|AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both|
BJ Shea, BC Reeves, G Wells, M Thuku, C Hamel, J Moran, D Moher, ...
bmj 358, 2017
|Improving the quality of reporting of randomized controlled trials: the CONSORT statement|
C Begg, M Cho, S Eastwood, R Horton, D Moher, I Olkin, R Pitkin, ...
Jama 276 (8), 637-639, 1996
|Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials|
JAC Sterne, AJ Sutton, JPA Ioannidis, N Terrin, DR Jones, J Lau, ...
Bmj 343, 2011
|The revised CONSORT statement for reporting randomized trials: explanation and elaboration|
DG Altman, KF Schulz, D Moher, M Egger, F Davidoff, D Elbourne, ...
Annals of internal medicine 134 (8), 663-694, 2001
|SPIRIT 2013 statement: defining standard protocol items for clinical trials|
AW Chan, JM Tetzlaff, DG Altman, A Laupacis, PC G°tzsche, ...
Annals of internal medicine 158 (3), 200-207, 2013
|Reprint—preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement|
D Moher, A Liberati, J Tetzlaff, DG Altman, Prisma Group
Physical therapy 89 (9), 873-880, 2009
|CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials|
KF Schulz, DG Altman, D Moher, CONSORT Group*
Annals of internal medicine 152 (11), 726-732, 2010